Iovance: Buy Now Before Many Growth Catalysts Kick In

Impact · against what's priced in

Iovance's raised 2026 revenue guidance and margin expansion projections provide a positive near-term catalyst. While the potential for a $10B+ addressable market via lung cancer and international expansion is highly bullish, the current stock momentum suggests some of the growth expectations are already being bid up.

IOVA+0.60

No priced-in read yet

In context

The raise in 2026 revenue guidance to $410–$420 million and the path toward 65–70% gross margins provide concrete catalysts for narrowing losses, while trial expansions into lung cancer could significantly increase the addressable market beyond current peak sales estimates.

Read from the article alone

• biotech
• healthcare
• IOVA
• cancer treatment
• clinical trials
• growth stocks
• lung cancer
• melanoma
• revenue guidance

Search tags